Search results
Showing 1306 to 1320 of 1367 results for patients and public
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder are set to benefit from a new treatment to help the skin wounds heal faster.
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
Updated tuberculosis guidelines will help target most vulnerable
Updated tuberculosis (TB) guidelines call for greater education and prevention to help target people from socially deprived backgrounds who are most vulnerable to contracting the infection.
Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE
NICE's strategy on sustainability: current progress and next steps
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE
Innovative approach that gets patients back into their own homes after hospital stay honoured
Newly introduced programme allowed those in hospital to reduce their length of stay by an average of six days
New drugs 'a major benefit' for patients with chronic hepatitis C
NICE has recommended the use of boceprevir (Victrelis) and telaprevir (Incivo), both in combination with peginterferon alfa and ribavirin, as options for the treatment of the most common strain of hepatitis C in adults, in latest guidance.
The NHS is being urged to tackle the rise in antibiotic resistance by cutting back on unnecessary use of the drugs.
NICE announces details of health technology evaluation methods review
Following approval at its recent Board meeting NICE has confirmed the details of its review of the methods it uses to develop guidance on drugs, medical devices and diagnostics.
NICE consults on changes to Interventional Procedures guidance programme
Proposals now out for consultation seek to formalise the involvement of medical device manufacturers
Today (Thursday 29 November), NICE opens a public consultation on its preliminary recommendations on the NHS use of the drug, pirfenidone (known commercially as Esbriet). The draft guidance assesses whether it should be recommended for use in people who have the lung condition, idiopathic pulmonary fibrosis.
NICE does not recommend elusulfase alfa for NHS use following evaluation of new evidence
NICE has today (12 November 2021) published draft guidance for public consultation which does not recommend elosulfase alfa (also called Vimizin and made by BioMarin) for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Nasal spray medicine for treatment-resistant depression not recommended by NICE
Consultation open on draft guidance until Friday 25 September 2020
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.